$VICR

D'Amico Andrew sold $439K of VICR

D'Amico Andrew sold 1,216 shares of VICOR CORP (VICR) at an average of $360.77 ($354.12–$367.10, $0.44M total) across 7 trades on 2026-06-22 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · D'Amico Andrew
Published Jun 24, 2026, 4:26 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 24, 2026, 4:44 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$VICR
Neutral
medium confidence
Mentioned
$VICR
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VICRNeutralLow
01

Why it matters

A director’s open-market sale under a 10b5-1 plan is generally not a strong fundamental signal, but it can influence short-term sentiment and positioning.

02

Market read

Traders may monitor for follow-on insider activity, but the disclosure alone is unlikely to drive a major repricing without accompanying fundamentals.

03

What to watch

The weighted-average price range ($354.12–$367.10) and the fact the director ends with 0 shares could matter for short-term sentiment, even if the plan reduces interpretability.

Relevance 3/10Novelty 5/10Timing: just filed Form 4 (filed 2026-06-24) disclosing 2026-06-22 insider sales

Background

The article is an SEC Form 4 insider transaction disclosure for ViCOR Corp (VICR).

Company-level read

Ticker impact

$VICRNeutralMedium confidence
Context

ViCOR Corp director Andrew D'Amico sold $438,702 of VICR shares via an open-market sale under a 10b5-1 plan, leaving 0 shares.

Expected impact

Likely limited immediate price impact; any effect is more sentiment/flow-driven than fundamental.

Evidence & confidence

The filing is a primary Form 4 disclosure, but it specifies a pre-arranged 10b5-1 plan and the transaction size is modest versus typical market caps, reducing fundamental read-through.

Market effects

No direct sector catalyst; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect routine liquidity rather than bearish expectations.

Key entities

  • VICOR CORP

    ViCOR Corp (VICR) disclosed an insider sale by director Andrew D'Amico via Form 4.

  • Andrew D'Amico

    Director who sold 1,216 shares across seven trades; holdings after transaction: 0 shares.

  • 10b5-1 plan

    Pre-arranged plan noted as Yes, indicating the sale was scheduled in advance.

Related articles

$VICRMedAI 8/10

Vicor (VICR) Q2 2026 Earnings Call Transcript

Vicor’s Q2 2026 earnings call reported product and royalty revenue of $143.4M, up 26.9% sequentially and 1.6% year over year. Advanced products revenue rose to $94.2M. Net income was $49.8M, GAAP diluted EPS $1.40, and cash was $453.6M. The company guided for nearly 10% Q3 revenue growth and over $600M 2026 revenue, citing capacity increases and licensing assumptions.

$VICRMed

Vicor Corp (VICR) Q2 2026 Earnings Call Highlights: Strong Revenue Growth

Vicor Corp said a new license agreement will bring $5 million quarterly payments in year one and $10 million in year two, with $15 million contributing to Q2 revenue and additional revenue recognition expected in Q3 and subsequent quarters. Management also discussed fab capacity expansion to support a $2.5 billion revenue goal and said backlog growth stems mainly from existing customer demand.

$VICRMed

VICOR CORP (VICR): Results of Operations and Financial Condition

VICOR CORP (VICR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d115827dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 NEWS RELEASE FINANCIAL NEWS BRIEF July 21, 2026 For Immediate Release Vicor Corporation Reports Results for the Second Quarter Ended June 30, 2026 Andover, Mass., July 21, 2026 (GLOBE NEWSWIRE) — Vicor Corporation (NASDAQ: